Abstract
Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections provide an overview of the risk factors for infectious complications, recommendations for infectious risk categorization, and strategies for prevention of infections in high-risk patient populations with cancer. Individualized risk evaluation for infections and incorporation of preventative measures are essential components of the overall spectrum of cancer care, and may contribute to optimizing treatment outcomes for patients.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Antifungal Agents / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Antiviral Agents / therapeutic use
-
Bacterial Infections / etiology
-
Bacterial Infections / immunology
-
Bacterial Infections / prevention & control*
-
Bacterial Infections / therapy
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunocompromised Host*
-
Mycoses / etiology
-
Mycoses / immunology
-
Mycoses / prevention & control*
-
Mycoses / therapy
-
Neoplasms / complications*
-
Neoplasms / drug therapy
-
Neoplasms / immunology
-
Neutropenia / chemically induced
-
Neutropenia / complications
-
Risk Factors
-
Virus Diseases / etiology
-
Virus Diseases / immunology
-
Virus Diseases / prevention & control*
-
Virus Diseases / therapy
Substances
-
Anti-Bacterial Agents
-
Antifungal Agents
-
Antineoplastic Agents
-
Antiviral Agents